Ilyang Pharmaceutical Launches Two Types of 'Dapaize Extended-Release Tablets' for Diabetes Blood Sugar Control

Improved Blood Sugar Control for Adults with Type 2 Diabetes

On December 4, Ilyang Pharmaceutical announced the launch of two types of Dapaize Extended-Release Tablets, a combination diabetes treatment for type 2 diabetes patients that combines the SGLT-2 inhibitor dapagliflozin and metformin to help control blood sugar levels.

Two types of diabetes treatment drug 'Dapaize Extended-Release Tablets'. Ilyang Pharmaceutical

The main ingredient in Dapaize Extended-Release Tablets, dapagliflozin, is an SGLT-2 inhibitor that directly lowers blood sugar by inhibiting glucose reabsorption in the kidneys. Metformin is one of the most widely used ingredients for adequate glycemic control in patients with type 2 diabetes.

The two types released are 'dapagliflozin anhydrous lactose mixture (15.27 mg) + metformin hydrochloride (500 mg)' and 'dapagliflozin anhydrous lactose mixture (15.27 mg) + metformin hydrochloride (1000 mg)'. Typically, patients take one tablet once daily with dinner.

A representative from Ilyang Pharmaceutical stated, "With the addition of Dapaize Extended-Release Tablets to our portfolio, following the combination drug Januga Tablets (sitagliptin and dapagliflozin) and Januarin Duo Tablets available in three dosages, we are expanding our range of diabetes treatments. We aim to increase our presence and sales in the diabetes market by offering a variety of treatment options."

This content was produced with the assistance of AI translation services.